History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019

The prior lipid-lowering therapy history of patients initiating PCSK9 inhibitors had not been characterized in a large US population, creating gaps in understanding the clinical context of PCSK9 inhibitor use.

Target RWE researchers characterized the history of lipid-lowering therapy use among adults initiating PCSK9 inhibitors, describing prior statin exposure, maximum tolerated doses, and evidence of statin intolerance in a real-world US commercial claims population.

Documenting that PCSK9 inhibitor initiators have extensive prior lipid-lowering therapy histories validates the real-world use of these agents in appropriate patient populations.

PCSK9 inhibitor initiator prior therapy characterization for label adherence and payer strategy evidence, Prior statin exposure evidence supporting PCSK9 inhibitor appropriate use and formulary arguments